Literature DB >> 24126745

Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244.

Mary N De Almeida1, Helen Heffernan, Anne Dervan, Sarah Bakker, Joshua T Freeman, Hasan Bhally, Susan L Taylor, Thomas V Riley, Sally A Roberts.   

Abstract

AIM: To compare disease severity and clinical outcome of Clostridium difficile infection (CDI) due to PCR-ribotype (RT) 244 with CDI due to other strains present in Auckland.
METHOD: A retrospective, case-control study was conducted. Ten cases with CDI due to RT 244 were compared with 20 controls infected with other C. difficile strains. RT 244 isolates were further analysed for antimicrobial susceptibility, binary toxin genes and mutations in the tcdC gene.
RESULTS: Cases were significantly more likely to have severe disease than controls (OR 9.33; p=0.015). 50% of cases had community-associated CDI compared with 15% of controls (p=0.078). All RT 244 isolates produced binary toxin and had a single-base pair deletion in tcdC at position 117.
CONCLUSION: C. difficile RT 244 is a newly recognised strain in New Zealand. It shares several features that characterise RT 027. Given its propensity to cause severe community-associated disease, a heightened awareness of this strain is needed to ensure early testing in patients admitted from the community with identified risk factors for CDI.

Entities:  

Mesh:

Year:  2013        PMID: 24126745

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  10 in total

Review 1.  Vaccines against Clostridium difficile.

Authors:  Rosanna Leuzzi; Roberto Adamo; Maria Scarselli
Journal:  Hum Vaccin Immunother       Date:  2014-03-17       Impact factor: 3.452

Review 2.  Diversity and Evolution in the Genome of Clostridium difficile.

Authors:  Daniel R Knight; Briony Elliott; Barbara J Chang; Timothy T Perkins; Thomas V Riley
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 3.  An Update on Clostridioides difficile Binary Toxin.

Authors:  Adrián Martínez-Meléndez; Flora Cruz-López; Rayo Morfin-Otero; Héctor J Maldonado-Garza; Elvira Garza-González
Journal:  Toxins (Basel)       Date:  2022-04-27       Impact factor: 5.075

Review 4.  Clostridium difficile infection: epidemiology, diagnosis and understanding transmission.

Authors:  Jessica S H Martin; Tanya M Monaghan; Mark H Wilcox
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-03-09       Impact factor: 46.802

5.  Laboratory-Based Surveillance of Clostridium difficile Infection in Australian Health Care and Community Settings, 2013 to 2018.

Authors:  Stacey Hong; Papanin Putsathit; Narelle George; Christine Hemphill; Peter G Huntington; Tony M Korman; Despina Kotsanas; Monica Lahra; Rodney McDougall; Casey V Moore; Graeme R Nimmo; Louise Prendergast; Jennifer Robson; Lynette Waring; Michael C Wehrhahn; Gerhard F Weldhagen; Richard M Wilson; Thomas V Riley; Daniel R Knight
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

6.  Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.

Authors:  D N Gerding; D W Hecht; T Louie; C E Nord; G H Talbot; O A Cornely; M Buitrago; E Best; S Sambol; J R Osmolski; H Kracker; H H Locher; P Charef; M Wilcox
Journal:  J Antimicrob Chemother       Date:  2015-10-03       Impact factor: 5.790

7.  Epidemiology of Clostridium difficile infection in two tertiary-care hospitals in Perth, Western Australia: a cross-sectional study.

Authors:  N F Foster; D A Collins; S L Ditchburn; C N Duncan; J W van Schalkwyk; C L Golledge; A B R Keed; T V Riley
Journal:  New Microbes New Infect       Date:  2014-04-01

8.  In Vitro and In Vivo Antibacterial Activities of a Novel Quinolone Compound, OPS-2071, against Clostridioides difficile.

Authors:  Daisuke Oka; Naomitsu Yamaya; Takuya Kuno; Yuta Asakawa; Toshiyuki Shiragiku; Liang Chen; Jingbo Xue; Abudusaimi Mamuti; Fangguo Ye; Jiangqin Sun; Kinue Ohguro; Hisashi Miyamoto; Yukitaka Uematsu; Katsuya Inagaki; Jie-Fei Cheng; Makoto Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 9.  Community-acquired Clostridium difficile infection: an increasing public health threat.

Authors:  Arjun Gupta; Sahil Khanna
Journal:  Infect Drug Resist       Date:  2014-03-17       Impact factor: 4.003

10.  Characterization of Clostridium difficile Strains in British Columbia, Canada: A Shift from NAP1 Majority (2008) to Novel Strain Types (2013) in One Region.

Authors:  Agatha N Jassem; Natalie Prystajecky; Fawziah Marra; Pamela Kibsey; Kennard Tan; Patricia Umlandt; Loretta Janz; Sylvie Champagne; Bruce Gamage; George R Golding; Michael R Mulvey; Bonnie Henry; Linda M N Hoang
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-03-29       Impact factor: 2.471

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.